Publications by authors named "Ani S Balmanoukian"
Article Synopsis
- The study evaluated the effectiveness of palbociclib, a targeted cancer therapy, in patients with advanced cancer exhibiting specific genomic alterations, focusing on two patient groups: those with head and neck cancer (HNC) and those with a mix of histologies (HP).
- Results showed that 40% of the HNC patients achieved disease control, which was statistically significant, while only 13% of the HP cohort did, failing to meet the criteria for significance.
- The treatment had notable side effects, with over 40% of patients experiencing serious adverse events, primarily blood-related issues like neutropenia and thrombocytopenia.
Microsatellite stable metastatic colorectal cancer (MSS mCRC; mismatch repair proficient) has previously responded poorly to immune checkpoint blockade. Botensilimab (BOT) is an Fc-enhanced multifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody designed to expand therapy to cold/poorly immunogenic solid tumors, such as MSS mCRC. BOT with or without balstilimab (BAL; anti-PD-1 antibody) is being evaluated in an ongoing expanded phase 1 study.
View Article and Find Full Text PDFArticle Synopsis
- The Targeted Agent and Profiling Utilization Registry Study is testing the effectiveness of targeted treatments for advanced lung cancer patients with specific genomic alterations.
- The study involved 28 patients, primarily with non-small-cell lung cancer, who received a combination therapy of pertuzumab and trastuzumab, aiming for disease control and measuring various outcomes, including overall survival.
- Results indicated a 37% disease control rate, with some patients showing a partial response, though there were also notable serious side effects from the treatment.
Purpose: The TAPUR Study is a pragmatic basket trial evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers harboring potentially actionable genomic alterations. Data from a cohort of patients with endometrial cancer (EC) with or amplification, overexpression, or mutation treated with pertuzumab plus trastuzumab (P + T) are reported.
Methods: Eligible patients had advanced EC, no standard treatment options, measurable disease (RECIST v1.
The sequential use of 1-/2-generation to 3-generation epidermal growth factor (EGFR) tyrosine kinase inhibitors (TKIs) has led to the emergence of triple EGFR mutations generally consisting of the founder mutation (del 19 or L858R), gatekeeper mutation (T790M) and mutation (C797S) that abolishes the covalent binding of osimertinib to the EGFR protein (i.e., del 19 or L858R/T790M/C797S).
View Article and Find Full Text PDFArticle Synopsis
- - MEDI1873 is an experimental treatment targeting GITR in patients with advanced solid tumors, evaluated in a phase I study focusing on safety, tolerability, and preliminary efficacy.
- - The trial involved 40 patients and tested various doses; while it was well tolerated at doses up to 500 mg, some experienced dose-limiting toxicities, with the most common side effects being headache, infusion reactions, and decreased appetite.
- - Despite showing some pharmacodynamic activity and stable disease in a portion of patients, further development of MEDI1873 is not planned due to the lack of significant tumor response.
Purpose: Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)-expressing nonsmall-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy and safety follow-up for patients with NSCLC treated with pembrolizumab monotherapy.
View Article and Find Full Text PDFBackground: The anti-programmed death 1 monoclonal antibody pembrolizumab has shown antitumour activity and is a first-line and second-line treatment option for patients with programmed death ligand 1 (PD-L1)-expressing advanced non-small-cell lung cancer. We report updated 3-year safety and efficacy outcomes from the phase 1 study, KEYNOTE-001.
Methods: KEYNOTE-001 is a multicohort, open-label, phase 1 study of pembrolizumab (2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks) in treatment naive or previously treated patients with locally advanced or metastatic non-small-cell lung cancer with measurable disease at baseline.
Purpose: Tumors may evade immunosurveillance through upregulation of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. Epacadostat is a potent and highly selective IDO1 enzyme inhibitor. The open-label phase I/II ECHO-202/KEYNOTE-037 trial evaluated epacadostat plus pembrolizumab, a programmed death protein 1 inhibitor, in patients with advanced solid tumors.
View Article and Find Full Text PDFMELANOMA BRIDGE 2015 KEYNOTE SPEAKER PRESENTATIONS Molecular and immuno-advances K1 Immunologic and metabolic consequences of PI3K/AKT/mTOR activation in melanoma Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu, Michael A.
View Article and Find Full Text PDFBackground: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of the PD-1 ligand 1 (PD-L1) that is associated with the likelihood of clinical benefit.
Methods: We assigned 495 patients receiving pembrolizumab (at a dose of either 2 mg or 10 mg per kilogram of body weight every 3 weeks or 10 mg per kilogram every 2 weeks) to either a training group (182 patients) or a validation group (313 patients).